TY - JOUR
T1 - Immunogenicity and protection-inducing ability of recombinant Plasmodium vivax rhoptry-associated protein 2 in Aotus monkeys
T2 - A potential vaccine candidate
AU - Rojas-Caraballo, Jose
AU - Mongui, Alvaro
AU - Giraldo, Manuel A.
AU - Delgado, Gabriela
AU - Granados, Diana
AU - Millan-Cortes, Diana
AU - Martinez, Paola
AU - Rodriguez, Raul
AU - Patarroyo, Manuel A.
N1 - Funding Information:
We thank Luis Carlos Esparragoza and Gabriela Arévalo for their technical support. We would also like to thank Nora Martinez for reviewing this manuscript. Special gratitude goes to Professor Manuel Elkin Patarroyo for his invaluable comments and suggestions. This research was supported by the “Instituto Colombiano para el Desarrollo de la Ciencia ‘Francisco Jose de Caldas’ (COLCIENCIAS)” contract RC-2008.
Copyright:
Copyright 2009 Elsevier B.V., All rights reserved.
PY - 2009/5/11
Y1 - 2009/5/11
N2 - Rhoptry proteins have been extensively shown to be important in invasion and parasitophorous vacuole (PV) formation. This work evaluates the immunogenicity and protective efficacy of Plasmodium vivax RAP2 in the non-human Aotus primate model, when expressed as a recombinant molecule in E. coli and formulated in Freund and Alum hydroxide adjuvants. Our results show that rPvRAP2 is immunogenic in both formulations, finding a trend of higher cytokine levels in immunized monkeys, specially in IL-4 levels (using Freund's adjuvant) and IL-5 (using Alum hydroxide). RAP2 is suggested as a P. vivax-vaccine candidate since immunized monkeys exhibited lower parasitemias than control groups after being experimentally challenged with the P. vivax VCG-I strain.
AB - Rhoptry proteins have been extensively shown to be important in invasion and parasitophorous vacuole (PV) formation. This work evaluates the immunogenicity and protective efficacy of Plasmodium vivax RAP2 in the non-human Aotus primate model, when expressed as a recombinant molecule in E. coli and formulated in Freund and Alum hydroxide adjuvants. Our results show that rPvRAP2 is immunogenic in both formulations, finding a trend of higher cytokine levels in immunized monkeys, specially in IL-4 levels (using Freund's adjuvant) and IL-5 (using Alum hydroxide). RAP2 is suggested as a P. vivax-vaccine candidate since immunized monkeys exhibited lower parasitemias than control groups after being experimentally challenged with the P. vivax VCG-I strain.
UR - http://www.scopus.com/inward/record.url?scp=64449088031&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=64449088031&partnerID=8YFLogxK
U2 - 10.1016/j.vaccine.2009.02.083
DO - 10.1016/j.vaccine.2009.02.083
M3 - Article
C2 - 19428897
AN - SCOPUS:64449088031
SN - 0264-410X
VL - 27
SP - 2870
EP - 2876
JO - Vaccine
JF - Vaccine
IS - 21
ER -
